hTIGIT Mouse Model
| Starin Name | C57BL/6N‑Tigit<sup>tm1Cin(hTIGIT)</sup> |
|---|---|
| Strain Background | C57BL/6N |
Applications
- Immuno-oncology Drug Evaluation: In vivoefficacy and pharmacodynamics assessment of anti-TIGIT monoclonal antibodies, bispecific antibodies, or combination therapies (e.g., anti-TIGIT + anti-PD-1/PD-L1).
- Checkpoint Inhibitor Safety Profiling: Evaluating the immune modulation and potential toxicities of TIGIT-targeted therapeutics.
- Tumor Immunology & Immune Regulation: Investigating TIGIT function on NK cells, CD8⁺ T cells, Tregs, and dendritic cells, and its co-inhibitory crosstalk with other checkpoints.
- Autoimmunity & Immune Homeostasis: Studying TIGIT-mediated suppression in autoimmune disease models and immune tolerance mechanisms.
Key Features
- Targeted Humanization: Murine Tigitextracellular domain replaced with human TIGITsequence via knock-in; intracellular domain retained to preserve physiological signal transduction.
- Authentic Ligand Interaction: Humanized ectodomain enables accurate binding to human TIGIT ligands (CD155/PVR, CD112/PVRL2), better mimicking human immune checkpoint engagement than wild-type mice.
- C57BL/6N Background: Established on the widely used C57BL/6N inbred background, facilitating integration with existing tumor and immunology models.
- Physiological Viability: Normal development and baseline immune cell composition maintained due to intact intracellular signaling motifs.
Strain Description
hTIGIT Humanized Knock-in Mouse Model (C57BL/6N-Tigittm1Cin(hTIGIT)/MC)
This model replaces the extracellular domain of the murine Tigitgene with the corresponding human TIGITsequence on the C57BL/6N background, while preserving the native intracellular signaling domain. It expresses a chimeric TIGIT protein with a humanized ectodomain and functional cytoplasmic tail, providing a physiologically relevant in vivoplatform for evaluating anti-TIGIT immunotherapies and dissecting TIGIT–CD155/PVRIG signaling in immune contexts.
FAQ
Game-changing benefits？
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.